The Series A round, which included participation from North Island Ventures and existing investors, brings New York-based Mural's total funding to $28 million.
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
Enterprises are deploying AI agents on top of incomplete and siloed workforce data that sit scattered across HR and finance systems and a decade of point solutions, each with its own definitions and blind spots.
Some of the most interesting moments in music production come when an arrangement won’t work. The groove is there and the melody is promising, but something
Failures of high-resolution MLLMs are commonly attributed to a visual problem, motivating zooming, cropping, and related visual interventions to recover fine-grained evidence or suppress interference. Yet recent studies suggest that relevant visual evidence is already encoded…
Perception for embodied agents is video-based, often multi-view (ego, exo, or both), and inherently continual, with simultaneous task and viewpoint shifts. Yet continual learning (CL) remains dominated by exo-only recognition tasks, obscuring behavior under these real-world…
Large language model (LLM) agents increasingly execute multi-step workflows through tool use and interaction with users and environments. However, current agent evaluations are largely English-centric, limiting our understanding of agent capabilities in multilingual settings.…
Robots operating in human-centered environments are typically designed to execute explicit instructions, and most robot-learning datasets likewise pair observations with task instructions or low-level actions. Although recent work has begun to explore proactive embodied…